International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.
about
Towards Stratified Medicine in Plasma Cell MyelomaA look backward and forward in the regulatory and treatment history of multiple myeloma: Approval of novel-novel agents, new drug development, and longer patient survival.Real-world use of pomalidomide and dexamethasone in double refractory multiple myeloma suggests benefit in renal impairment and adverse genetics: a multi-centre UK experience.Efficacy and tolerability of the histone deacetylase inhibitor panobinostat in clinical practice.Plasma cell neoplasia after kidney transplantation: French cohort series and review of the literature.IAP antagonists induce anti-tumor immunity in multiple myeloma.Diagnosis and monitoring for light chain only and oligosecretory myeloma using serum free light chain tests.PET Imaging for Initial Staging and Therapy Assessment in Multiple Myeloma Patients.Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial.Outcomes of maintenance therapy with lenalidomide or bortezomib in multiple myeloma in the setting of early autologous stem cell transplantation.Quantitative PCR: an alternative approach to detect common copy number alterations in multiple myeloma.Oligoclonal Pattern/Abnormal Protein Bands in Post-Treatment Plasma Cell Myeloma Patients: Implications for Protein Electrophoresis and Serum Free Light Chain Assay Results.Current and developing synthetic pharmacotherapy for treating relapsed/refractory multiple myeloma.Utilizing next-generation sequencing in the management of multiple myeloma.End points and statistical considerations in immuno-oncology trials: impact on multiple myeloma.Analysis of a Compartmental Model of Endogenous Immunoglobulin G Metabolism with Application to Multiple Myeloma.Therapy assessment in multiple myeloma with PET.Modern multiple myeloma therapy: deep, sustained treatment response and good clinical outcomes.How is patient care for multiple myeloma advancing?Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical TrialsNew developments in the treatment of multiple myeloma - clinical utility of daratumumab.Daratumumab for the treatment of multiple myeloma.Association between response rates and survival outcomes in patients with newly diagnosed multiple myeloma. A systematic review and meta-regression analysis.Next-generation multiple myeloma treatment: a pharmacoeconomic perspective.Developments in the Field of Myeloma in the Last Decade.Allogeneic Hematopoietic Cell Transplantation for Myeloma: When and in Whom Does It Work.The Critical Role of Imaging in the Management of Multiple Myeloma.Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysisHigh sensitivity blood-based M-protein detection in sCR patients with multiple myeloma.Quantitative analysis of 18F-NaF dynamic PET/CT cannot differentiate malignant from benign lesions in multiple myeloma.Serial measurements of circulating plasma cells before and after induction therapy have an independent prognostic impact in patients with multiple myeloma undergoing upfront autologous transplantation.Circulating tumor cells as a biomarker for response to therapy in multiple myeloma patients treated within the GMMG-MM5 trial.Prospective Identification of Oligoclonal/Abnormal Band of the Same Immunoglobulin Type as the Malignant Clone by Differential Location of M-Spike and Oligoclonal Band.11C-Methionine-PET in Multiple Myeloma: A Combined Study from Two Different Institutions.Pomalidomide in the treatment of multiple myeloma: design, development and place in therapy.Analytical and clinical validation of a novel in-house deep-sequencing method for minimal residual disease monitoring in a phase II trial for multiple myelomaNext Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma.The prognostic value of the depth of response in multiple myeloma depends on the time of assessment, risk status and molecular subtype.Deep and sustained response after venetoclax therapy in a patient with very advanced refractory myeloma with translocation t(11;14).New Developments in Diagnosis, Prognosis, and Assessment of Response in Multiple Myeloma.
P2860
Q28074994-FA314282-CFEC-4D11-80BD-796C13CE31AEQ30239781-8A23059F-7B95-4252-AD82-F089DE1D515AQ33439437-F560B7C3-62AE-4B4D-BF92-8F691B83BA12Q33443417-8532D8F3-B69D-4B70-9851-3693CB6C927CQ33821866-B50E6922-D496-4437-845C-81CD2901708AQ33914862-F4DF1660-EF2F-4F2A-9A8B-96BAF204382EQ34557435-15EAB9EC-C855-476E-BC38-676CFA22BCB4Q37691050-D548B31B-19AC-4969-8ADF-440990347C5AQ38371861-29B35ABB-5AB6-4A27-9B04-E75F88FEE4D5Q38605030-3C2DE547-37A4-4B9D-8641-F18E88A4B421Q38645307-BEBC69F0-93C8-431A-A8DE-EFEF9EA22C08Q38671274-0F621708-AA9E-44A3-8C20-6A666E0B1A52Q38672091-D74B025D-1BBF-4EF8-896E-941E8FA548BBQ38681814-BF101464-EC88-4AE6-8740-BCDB46D0C6F5Q38732370-A4CB045E-71B9-44D0-810F-648FFB869552Q38736404-7FA33A44-C51E-4145-9E62-BF708EDA8C38Q38749648-3B5CE33D-C0E9-424B-A654-ED158E886C53Q38756800-E173E896-25C1-41B4-B0B7-1012177948D1Q38786149-3C13F258-BCFA-4F0B-BB78-0C26792E7F91Q38789282-B16BE635-0601-4AEB-9E6A-69FD01955021Q38820002-F6AFA760-568D-451E-B4AE-EF12631E3EC9Q38824538-4CFAE441-6AAB-4DCA-A1BF-EABA417337EEQ38971754-97CCE109-34B3-4CDB-99BB-FEF56D29E264Q38981247-DC64A540-D54E-470C-B3E1-3D6F5F6C41CAQ39134193-1E4BDAAE-74DD-4C5E-8C35-AFA8E37EB391Q39174731-E7E2298C-623C-4A09-8ED7-12CCF9E6F1EDQ39186780-8B47C079-8B1F-4463-A677-CA278F78321EQ40594905-7D65F4CF-B1EE-4673-BC2D-1BDDCDDB0088Q41176998-8153A82B-DF7F-4AA5-BF85-5F4354BEB9B7Q41180773-5B4BF390-765A-4974-83F1-EAF3BA0838F7Q41230421-F329640F-A9F8-4E62-B0C5-5458D14A687DQ41245090-A0D17B5B-B364-4E38-940C-A1BB96611053Q41353932-3BFCFE96-46F9-4AB3-8ADE-C33A43DED54AQ41455546-B72278F3-ECF6-49A9-B93E-F9282599FE9EQ41545464-B854DE3F-1DE0-4196-A350-872CC56EB9B3Q41984297-47AF1D6B-3E1B-41BD-83D8-FADE2419085BQ42050819-A52B095D-709C-4D3A-9822-9F541D5F6EE6Q42341707-B8355900-16B6-4347-8DB7-AC6AE10ABFC5Q42362001-4045352B-DE22-43FE-A553-9FD7C7238EF6Q43402624-92C812D2-5AD6-446E-9A4F-27EEEEB03C09
P2860
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
International Myeloma Working ...... ssessment in multiple myeloma.
@en
type
label
International Myeloma Working ...... ssessment in multiple myeloma.
@en
prefLabel
International Myeloma Working ...... ssessment in multiple myeloma.
@en
P2093
P50
P1433
P1476
International Myeloma Working ...... ssessment in multiple myeloma.
@en
P2093
Alberto Orfao
Andrew Spencer
Anthony Reiman
Brian Durie
Bruno Paiva
Elena Zamagni
Evangelos Terpos
Jean-Luc Harousseau
Jens Hillengass
Jesus San Miguel
P304
P356
10.1016/S1470-2045(16)30206-6
P50
P577
2016-08-01T00:00:00Z